Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Universal T-cell epitopes for anti-malarial vaccines

An anti-malarial and malaria technology, applied in the field of vaccines with universal T-cell epitopes, can solve the problem of vaccines failing to trigger immune responses, etc.

Inactive Publication Date: 2000-02-09
NEW YORK UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If T-cell epitopes contained in synthetic malaria vaccines bind only a limited range of class II molecules, the vaccines may fail to elicit an immune response in individuals with different genetic backgrounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Universal T-cell epitopes for anti-malarial vaccines
  • Universal T-cell epitopes for anti-malarial vaccines
  • Universal T-cell epitopes for anti-malarial vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] The following examples are intended to serve as non-limiting illustrations of the invention. Example 1: Anti-malarial vaccines containing MAP

[0092] Studies in mice of different genetic backgrounds have shown that: * Peptide-based vaccines of epitopes (see above) are immunogenic when unadjuvanted (ie when administered alone in phosphate buffered saline).

[0093] Enhanced antibody responses were obtained by adding adjuvants such as alum (Rehydragel, Reheis NJ) or QS21 (CambridgeBiotech, Cambridge MA).

[0094] A typical antimalarial vaccine containing MAP has 1 mg mixed with 100 μg QS21 (T * T1B) 4 map. This vaccine is given by injection under the skin. Example 2: Eliciting CS-specific antibodies in humans

Embodiment 2

[0094] A typical antimalarial vaccine containing MAP has 1 mg mixed with 100 μg QS21 (T * T1B) 4 map. This vaccine is given by injection under the skin. Example 2: Eliciting CS-specific antibodies in humans

[0095] The following studies were performed to examine the immunizing effect of a vaccine containing a universal T-cell epitope on a variety of humans with different genetic backgrounds.

[0096] METHODS: A compound called (T1BT * ) 4 - Polyoxime synthetic malaria vaccine of P3C. The vaccine contains universal T cell epitopes as described above (T * ) and a 28-residue repeat (DPNANPNV) derived from the Plasmodium falciparum CS repeat 3 (NANP) 3 (called T1B) combined. The vaccine also contains a covalently linked synthetic adjuvant tripalmitoylcysteine ​​(Pam 3CyS) attached to the lysine core. Methods for the synthesis of immunogenic polyoxime compositions are disclosed in International Patent Application WO 94 / 25071. for T * Methods for the synthesis of polyox...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods and compositions for eliciting protective immunity against malaria. In particular, the invention relates to universal T-cell epitopes that elicit T-cell responses in individuals of differing genetic backgrounds. Immunogenic compositions and vaccines including malaria-specific universal T-cell epitopes are disclosed.

Description

[0001] This application claims priority under 35 U.S.C. §119 from Provisional Application No. 60 / 033,916 filed January 27, 1997, the disclosure of which is incorporated herein by reference in its entirety. field of invention [0002] The present invention relates to vaccines effective in inducing protective immunity against malaria, in particular vaccines comprising universal T cell epitopes that elicit T cell responses in individuals of different genetic backgrounds. Background of the invention [0003] The public health problem caused by malaria, which currently infects 400 to 500 million people worldwide, is exacerbated by the emergence of multidrug-resistant parasite strains and insecticide-resistant mosquito vectors. These developments have led to increased efforts to provide effective vaccines to prevent mortality and morbidity due to malaria, particularly P. falciparum. Plasmodium falciparum is the most virulent species of Plasmodium. [0004] In mammalian hosts, mal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/015A61K39/295A61K39/00A61P33/06C07K7/08C07K14/445
CPCC07K7/08A61K2039/57Y10S530/806Y10S530/822A61K39/295A61K39/015C07K14/445A61P33/06Y02A50/30
Inventor E·纳丁A·莫莱诺
Owner NEW YORK UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com